Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Anouk K M ClaessensMonique E M M BosMarta Lopez-YurdaJeanette M BoumaJeany M Rademaker-LakhaiAafke H HonkoopHiltje de GraafEdith van DrutenLaurence J C van WarmerdamMaurice J C van der SangenVivianne C G Tjan-HeijnenFrans L G Erdkampnull nullPublished in: Breast cancer research and treatment (2018)
EudraCT 2010-021519-18; BOOG 2010-02.
Keyphrases